Allergy: Arkansas considers PSE switch to Rx-only
As Drug Store News suggested last month, legislation under consideration in Tennessee and Kentucky that would make the popular decongestant pseudoephedrine only available by prescription has, in fact, sparked interest in neighboring states. Arkansas shares a border with Kentucky, where a PSE prescription-only bill was filed in January, and Mississippi, one of two states that already has passed PSE prescription-only legislation.
Nationally, sales of the top-three best-selling PSE products — Claritin-D, Mucinex D and Zyrtec-D — were up 4.3% to $62.1 million across food, drug and mass (minus Walmart) for the 12 weeks ended Jan. 23, according to SymphonyIRI Group data.
Sales of all cough-cold products were up 6.8% to $1.4 billion. Heading into March, between 14% and 16% of the population were experiencing an upper respiratory ailment, according to the Chestal Cold & Flu Tracker sourcing SDI data.
The article above is part of the DSN Category Review Series. For the complete Allergy Sell-Through Report, including extensive charts, data and more analysis, click here.
Homeopathy profits from PSE recalls
BUFFALO, N.Y. — Last year’s recalls have put many popular children’s cough-cold medicines in the headlines and off the shelves. Couple that factor with the debate over safety and efficacy of these products, and you have a market primed for just as efficacious but safer introductions, like those in the homeopathic sector.
“The past issues with pediatric cold medicines have been great for homeopathy and the natural segment,” said Michele Boisvert, Homeolab USA president. “There is certainly an increased amount of homeopathic and natural offerings on the shelves today for consumers to choose from,” she said. “And now with recent recalls, it leaves the door wide open for natural options.”
Hyland’s covers ‘life cycle’ of products
NEW YORK — The new marketing frontier of social media has created new opportunities to reach a very passionate consumer, and that may be one big reason behind homeopathy’s escalating penetration with the general public.
That’s especially true for a niche marketer like Hyland’s, a company that has developed a “life cycle” of products of sorts by providing solutions applicable to newborn babies and toddlers, such as teething gel and colic tablets; remedies for older children as part of its Hyland’s “4Kids” brand; and homeopathic remedies more appropriate for adults.
“The purchaser of a teething tablet is going to have different attributes than a consumer and/or purchaser of an adult cough-cold product,” said J.P. Borneman, chairman and CEO at Hyland’s. “In the baby product area, the consumer is a passionate Hyland’s mom. … That’s an entirely different proposition than the adult cold or the leg-cramp user.”
Also helping bridge the gap is a comprehensive Web presence, including both traditional Web portals and newer social media portals, such as Facebook. That strategy has paid dividends, Borneman noted. “Sometimes those smaller [niche markets] have significantly higher loyalty and stickiness. … That also means that what’s growing is growing in a more robust and stable way.”